Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3926 - International comparison of stage-specific treatment of and survival from colorectal cancer: England, Norway and Sweden, 2010-2012

Date

09 Sep 2017

Session

Poster display session

Presenters

Sara Benitez Majano

Citation

Annals of Oncology (2017) 28 (suppl_5): v158-v208. 10.1093/annonc/mdx393

Authors

S. Benitez Majano, C. Di Girolamo, M. Morris, B. Rachet, M.P. Coleman, S. Walters

Author affiliations

  • Non-communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, WC1E 7HT - London/GB
More

Resources

Abstract 3926

Background

Colorectal cancer patients in England have worse outcomes than patients diagnosed in other high-income countries with similar healthcare coverage. We aim to compare clinical characteristics and survival of colorectal cancer patients in England, Norway and Sweden to understand whether differences in stage and treatment could help to explain international differences in survival.

Methods

Information on patients aged 15-99 years diagnosed with primary malignant tumours of the colon and rectum in England, Norway and Sweden during 2010-2012 was extracted from national cancer registration and/or specialised colorectal cancer registry data. Six-month, one-year and two-year net survival was estimated for each country, stage at diagnosis, and surgical treatment status.

Results

There were 93,125 colorectal cancer diagnoses in England, 11,155 in Norway, and 17,925 in Sweden during the time period. Stage was more advanced in colon than in rectal tumours. England had slightly poorer stage distribution, and a higher proportion of missing stage, than Norway and Sweden. Overall, 64.1% of colorectal cancer patients diagnosed in England, 68.8% diagnosed in Norway and 70.3% diagnosed in Sweden had evidence of receiving potentially curative surgery. These surgically treated patients were on average younger in England than in Norway and Sweden, in each stage category. Stage-specific net survival was generally highest in patients in Sweden and lowest in those in England. The survival deficit of English patients was particularly large compared to similar patients in the other countries among those diagnosed with advanced disease and/or who did not receive potentially curative surgery.

Conclusions

Stage-specific survival from colorectal cancer in England was lower than in Norway and Sweden. This survival deficit may be partly explained by the higher proportion, and lower survival, of patients who did not receive potentially curative surgery in England. The different proportions of missing data may somewhat affect the comparability of the results; however these remain informative.

Clinical trial identification

Legal entity responsible for the study

Cancer Survival Group, London School of Hygiene and Tropical Medicine

Funding

Cancer Research UK

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings